Garaventa A, Ladenstein R, Chauvin F, Lanino E, Philip I, Corciulo P, Brisigotti M, Favrot M, Dini G, Philip T
Bone Marrow Transplant Unit, Giannina Gaslini Institute, Genova, Italy.
Eur J Cancer. 1993;29A(4):487-91. doi: 10.1016/s0959-8049(05)80136-4.
In order to better evaluate the role of bone marrow purging procedures in the treatment of stage IV neuroblastoma, two similar groups of patients, prospectively treated during the same period at Léon Bérard Center, Lyon, France, and at Giannina Gaslini Institute, Genova, Italy, were reviewed. 18 children were treated in Lyon with a protocol including induction chemotherapy, surgery and a single course of high-dose chemotherapy followed by purged autologous bone marrow rescue. 21 patients were treated in Genoa with a very similar protocol which did not include purging procedures. Progression-free survival at 6 years was 12% (95% confidence interval 0-24%), without any difference between the two series of patients. The only prognostic factor for long-term survival was the persistence (or not) of bone lesions and the presence of metastatic disease (bone or bone marrow) at graft. The small numbers in the two groups and the very poor outcome make it difficult to conclude on the efficacy of purging.
为了更好地评估骨髓净化程序在IV期神经母细胞瘤治疗中的作用，对在法国里昂的莱昂·贝拉尔中心和意大利热那亚的吉安尼娜·加斯利尼研究所同期进行前瞻性治疗的两组相似患者进行了回顾。18名儿童在里昂接受了一项方案治疗，该方案包括诱导化疗、手术和一个疗程的大剂量化疗，随后进行净化自体骨髓挽救。21名患者在热那亚接受了非常相似的方案治疗，但该方案不包括净化程序。6年无进展生存率为12%（95%置信区间0-24%），两组患者之间无任何差异。长期生存的唯一预后因素是骨病变的持续存在（或不存在）以及移植时转移疾病（骨或骨髓）的存在。两组病例数较少且预后极差，难以就净化的疗效得出结论。
